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HypvrtennUm Case Report
Severe Hypertension in Childhood Due to Prolonged
Skin Application of a Mineralocorticoid Ointment
ANTONIO BARTORELLI AND ANDREA RIMONDINI
SUMMARY We report the case of a 9-year-old boy suffering from exzematous dermatitis who was
treated for 6 years with a daily dose of 100 mg of a dermatological ointment containing 9,-fluoro-
prednisolone-21-acetate. At examination the patient's blood pressure was persistently 230/160 mm Hg
and was considered essential in origin after secondary forms of arterial hypertension had been
excluded. Treatment with nifedipine and labetalol lowered the blood pressure to 150/100 mm Hg.
When we became aware of the dermatological treatment, we advised its discontinuance. In the
subsequent 7 days, the blood pressure fell to hypotensive levels (75/40 mm Hg) and then became
normal a few days after discontinuance of the antihypertensive therapy. This case suggests that
prolonged use of topical steroids, commonly prescribed for skin diseases, may cause hypertension,
especially in childhood. (Hypertension 6: 586-588, 1984)
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V ARIOUS agents such as drugs, poisons, andfood can induce hypertension by interferingwith mechanisms that regulate arterial pres-
sure.1 2 Mineralocorticoid administration elevates
blood pressure through retention of sodium.3"5 We re-
port a case in which severe hypertension resulted from
prolonged application of a dermatological ointment
containing a potent mineralocorticoid.
Case Report
A 9-year-old boy was admitted to our Hypertension
Unit in June, 1981, because of severe hypertension.
Blood pressure had first been found elevated (240/140
mm Hg) 4 months earlier during a routine medical
examination. There was no family history of hyperten-
sion. Childhood diseases had included measles, ru-
bella, and chicken pox, all of which had followed a
benign course. A twin brother had been operated on
successfully for a medulloblastoma of the cerebellum.
Examination
On admission, the patient had a blood pressure of
230/160 mm Hg supine and 220/160 mm Hg upright
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with no differences between measurements of the up-
per and lower parts of the body. The patient was
asymptomatic, and physical examination was normal
except for a cardiac gallop rhythm. Electrocardiog-
raphy (ECG) showed voltage changes due to ventricu-
lar hypertrophy and mild repolarization abnormalities;
Grade II hypertension retinopathy was evident. Labo-
ratory tests documented normal renal function and
moderate hypokalemia; plasma and urine catechola-
mine and aldosterone concentrations and plasma renin
activity were normal (Table 1). Angiography ruled out
renal artery stenosis and coarctation of the aorta.
TABLE 1. Laboratory Findings
Laboratory study
Serum potassium
Plasma aJdosterone
supine
upright
Urinary aJdosterone
Plasma renin activity
supine
upright
Plasma norepinephrine
Plasma epinephrine
Urinary catecholamine
Values
3.0 mEq/liter
75 pg/ml
130 pg/ml
9.3 jtg/24 hr
0.27 ng-mr'-hr-'
O^Sng-ml-'hr"1
0.263 ftg/liter
0.075 jig/liter
74 /ig/24 hr
Normal
range*
(3.5-5)
(12-125)
(70-295)
(5-15)
(0.16-0.66)
(0.73-2.13)
(0.12-0.28)
(0.03-0.08)
(10-80)
•Normal range in our laboratory.
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FIGURE 1. Supine (solid lines) and upright (doited lines) systolic and diastolic blood pressure levels in the untreated condition,
under labetalol plus nifedipine treatment, and during the 2-year follow-up after discontinuance of the ointment and antihypertensive
drug.
Treatment
The patient was treated first with an alpha- and beta-
blocking agent (labetalol, 200 mg four times daily),
which was partially effective. Subsequently, labetalol
was combined with a calcium-channel-blocking agent
(nifedipine, 20 mg four times daily), which lowered
the supine and upright blood pressures to 150/100 mm
Hg (Figure 1).
Course
The patient was discharged from the hospital under
this therapeutic regimen. When he returned to our
Hypertension Unit 10 days later for a periodic check-
up, we noticed eczematous lesions on the forehead.
The mother said that these lesions reappeared when-
ever administration of a skin ointment was discontin-
ued. She also reported that these lesions had been
evident a few weeks after birth and were diagnosed as
atopic eczematous dermatitis of the legs, arms, and
face. When her son was 3 years old, a physician pre-
scribed a dermatological ointment to alleviate his itch-
ing and scratching. The eczematous lesions and pruri-
tus regressed afterward but returned within a few days
after discontinuance of the treatment. The mother had
therefore continued to spread the ointment on the
child's skin and rubbed it over nearly the entire surface
of the body until completely absorbed.
The compound was found to contain a potent miner-
alocorticoid (9a-fluoroprednisolone-21-acetate) in the
concentration of 10 mg per gram; it was formulated as
an ointment in a greasy, water-insoluble base. We
estimated that this child had received approximately
100 mg of the fluorinated steroid per day during the
previous 6 years. We suspected that the ointment was
related to the blood pressure elevation and immediate-
ly discontinued it while maintaining antihypertensive
therapy.
After 7 days, the patient returned complaining of
dizziness and lightheadedness, and faintness during
exercise. Blood pressure was found to be 75/40 mm
Hg when the patient was both supine and upright.
Antihypertensive treatment was immediately discon-
tinued, and the blood pressure returned to normal with-
in a few days (Figure 1).
During the last 24 months, the blood pressure has
remained 120/80 mm Hg without any treatment; fundi
and electrocardiogram have reverted to normal.
Discussion
Since 1952 when Sulzberger and Witten6 reported
the beneficial effects of cortisol on skin lesions, corti-
costeroids in topical preparations have gained in popu-
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larity. Although they may be regarded as the most
commonly prescribed preparations for treatment of
skin diseases,7 little attention has been devoted to their
potential systemic effects. Accumulated evidence,^'2
however, indicates that topically administered steroids
can be absorbed through the skin and that the risk of
serious systemic effects exists when high doses are
used for long periods of time over large areas of the
body. The magnitude of percutaneous absorption is
related mainly to the concentration and potency of the
drug, the severity of the dermatitis, the frequency,
method, and extent of application, and the vehicle
used.'3 Ointments are very effective since they form an
occlusive layer, which increases the hydration of the
stratum comeum epidermidis and, consequently, the
penetration of the active constituent. Adverse effects
observed with highly potent topical mineralocorticoids
include suppression of pituitary-adrenal function,13"16
development of Cushing's syndrome,17"20 and changes
in urinary electrolyte excretion and urine volume, so-
dium retention, and edema.14"21 -n Blood pressure
elevation has been associated with hypokalemia, alka-
losis, suppressed plasma renin activity, and low aldo-
sterone plasma levels in cases of habitual use of
large doses of nasal drops containing 9 -fluoroprednis-
olone.23"25
There is little doubt that the hypertension in this case
was caused by the topical mineralocorticoid. Family
history was negative, laboratory and angiographic
studies excluded secondary forms of hypertension, and
ointment discontinuance promptly resulted in symp-
tomatic hypotension followed by normal blood pres-
sure when antihypertensive treatment was withdrawn.
Failure to find depressed plasma renin activity, which
would have been predictable, is not fully understood
given the available data. However, it may have been
that the plasma renin activity was considered normal
when indeed it reflected suppression of renin secre-
tion, as suggested by the finding during follow-up of
renin levels consistently exceeding those detected be-
fore ointment discontinuance. Apart from the potency
and high dosage of the mineralocorticoid, which was
applied for a long period of time over large areas of the
body, the age of the patient may have played an impor-
tant role. Compared with adults and in relation to body
weight, children have a greater proportion of body
surface area and a relatively thinner skin. Their absorp-
tion of drugs through the skin may be enhanced as is
the likelihood of the development of systemic effects.
This case emphasizes that the medical history
should be accurate and detailed and should include
specific inquiries concerning use of skin ointments
containing powerful fluorinated steroids. This case
also emphasizes the need to carefully monitor patients
under prolonged treatment with topical preparations
containing fluorinated steroids; this may be particular-
ly true in childhood.
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